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Mounting evidence indicates an involvement of inflammation in the pathogenesis 
of Alzheimer’s disease. While there are other mechanisms involved, it is this role of 
inflammatory processes that we wish to investigate. Triptolide is the major constituent in 
the Chinese herb, Tripterygium wilfordii Hook F, and has been used for centuries as part of 
Chinese herbal medicine. The four ringed structure has close homology to drugs of the 
steroid class and it has been shown to be beneficial as an anti-inflammatory for rheumatoid 
arthritis and for treatment of certain cancers. The aim of this study was to evaluate the 
potential therapeutic effect of Triptolide on the neuropathology and deficits of spatial 
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learning and memory in amyloid precursor protein (APP) and presenilin 1 (PS1) double-
transgenic mice, a well established Alzheimer’s disease (AD) mouse model. After 
treatment of APP/PS1 mice with Triptolide (40µg/kg, three times weekly,), initiated when 
the mice were 5 months old, for as little as 8 weeks, significant decrease in β-amyloid (Aβ) 
deposition and microglia activation was observed. Moreover, Triptolide treatment robustly 
rescued spatial memory deficits observed in APP/PS1 mice. However, APP processing, tau 
hyperphosphorylation, and the activities of the two major kinases involved in tau 
hyperphosphorylation, cyclin dependent kinase 5 (cdk5) and glycogen synthase kinase 3β 
(GSK3β) were not affected by the Triptolide treatment. Based on the recent finding for the 
inhibitory effect of Triptolide on Aβ-induced production of pro-inflammatory cytokines 
from microglia, we propose that Triptolide treatment may have beneficial properties in 
halting glial activation and help restore an immune system that fights plaque deposition. 
Although the exact mechanism of action has yet to be deduced, the increase in APP CTFs 
while having a significant decrease in amyloid plaque deposition suggests that alterations 
in gamma secretase activity may be a possible answer. Currently, these results support the 
use of Triptolide as an effective therapeutic to prevent the progression of Alzheimer’s 
disease. 
 
Key words: Alzheimer’s disease, triptolide, APP processing, microglia, astrocytes 
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Introduction 
 
 
Today, Alzheimer’s disease (AD) is the number one cause of dementia in the 
elderly. Dementia refers to a progressive decline in cognitive function due to neuronal 
damage that is unlike the normal aging process. As of now, there is no cure and the 
degeneration of neurons coupled with secondary complications from sedentary behavior 
will eventually lead to the death of the patient. It was first described by Alois Alzheimer in 
1901, a German psychiatrist who described his patient as having symptoms of strange 
behavior and short-term memory loss. Subsequent examination of the patient’s brain 
showed amyloid plaque deposition and neurofibrillary tangles, two major hallmark 
pathologies associated with AD. Current treatments consist of acetylcholinesterase 
inhibitors (donepezil, galantamine, rivistigmine) and the drug memantine, which is an 
NMDA receptor antagonist. The NMDA receptor is an ionotropic glutamate receptor 
which when activated will open and allow the flow of cations in and out of the cell. 
Synaptic plasticity plays an important role for learning and memory and calcium flux 
through the NMDA receptor upon activation is thought to be critical in this process. It is 
well known that AD brains show a reduction in cholinergic neuron activity due to 
degeneration of these neurons, thus acetylcholinesterase inhibitors are used to increase the 
concentration of acetylcholine in the brain, thereby maintaining the activity of cholinergic 
neurons. Although hotly debated, some believe that excitotoxicity from excess glutamate is 
also a feature of AD and memantine’s activity at NMDA receptors blocks this 
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overstimulation from glutamate. These drugs represent symptomatic treatments, not 
mechanistic or cause-based treatment and thus have no indication for delaying or halting 
the progression of neurodegeneration. As a side note, part of memantine’s controversial 
mechanisms of action are a result of some clinical trials showing that patients receiving 
memantine retained cognitive functions longer than those not taking it, suggesting a delay 
in the progression of AD. 
 The need for a definitive treatment that has the ability to halt or delay further 
neurodegeneration cannot be emphasized enough. Currently, there are approximately 5 
million cases of AD in the United States, costing over $350 billion per year. These 
numbers are expected to escalate to over 15 million cases at a cost of over $1 trillion per 
year by 2050.  This is predicted because the average lifespan has more than doubled since 
1840 and furthermore, we face increasing numbers of people over the age of 65 that 
require more and more medical care (Figure 1). If nothing is done to reverse and/or treat 
this disease, we face an epidemic of neurological diseases that encompass not only AD, but 
Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), and many more.  
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Percentage of Older Adults who have Alzheimer's Disease, by Age 
 
 
Figure 1 Chart reflecting the percentage of adults in the United States who have AD. As the age of the 
population increases, the chances of developing AD increases exponentially. 
 
 (Figure from http://aspe.hhs.gov/health/Reports/medicalinnovation/, US Dept. of HHS) 
 
APP Processing and the Amyloid Hypothesis 
Aβ plaque deposition begins when the amyloid precursor protein (APP), a type I 
transmembrane glycoprotein, undergoes endoproteolytic cleavage by β-site APP cleaving 
enzyme 1 (BACE1, β-secretase), producing a secreted ectodomain of APP and the C99 
membrane-bound fragment of the remaining APP protein. The C99 fragment becomes the 
substrate for subsequent cleavage by another protease, γ-secretase, which produces the 
carboxyl terminus of Aβ and subsequently, the mature peptide is secreted from the cell to 
aggregate with other Aβ peptides to form amyloid plaques. The cleavage by γ-secretase is 
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not always specific and will produce fragments that vary in their amino acid length. 
However, the majority of fragments produced by γ-secretase contain either 40 or 42 amino 
acids, referred to as Aβ40 and Aβ42. It has been shown that insoluble, oligomeric Aβ40/42 
(Jiao, Xue et al. 2008) is more pathologically relevant to the degenerative effects of AD 
than other monomers and oligomers of different lengths.  Another enzyme involved in 
APP processing, α- secretase, cleaves APP in the middle of the Aβ domain which 
precludes the formation of Aβ plaques. This can be considered ‘normal’ APP processing 
and is referred to as the non-amyloidogenic pathway in APP processing (Vassar 2002). 
The importance of BACE1 in the progression of AD is that it has been identified as the 
first enzyme that cleaves the APP protein and results in an increase in Aβ deposition. This 
may be the initial cause which “gets the ball rolling” in a pathological state. Indeed, the 
introduction of BACE1 siRNA through lentiviral vectors has been shown to ameliorate AD 
pathologies and neural deficits in vivo (Singer, Marr et al. 2005). 
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Figure 2 Diagram of APP processing. In the amyloidogenic pathway, sequential cleavage of APP by BACE1 
and γ-secretase yields fragments of Aβ 40 and 42, referring to the amino acid length. These dimerize and 
oligomerize into amyloid plaques. 
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Figure 3 In the non-amyloidogenic pathway, APP is sequentially cleaved by α-secretase followed by γ-
secretase which yields CTFs and AICD. The cleavage of APP is within the Aβ domain which precludes the 
formation of Aβ plaques. This can be thought of as the “normal” processing of APP. 
 
Until recently, the amyloid hypothesis was by consensus the leading theory on which the 
research community based their work around. It allowed scientists to focus on a specific 
set of pathologies that could possibly yield therapeutic breakthroughs. Part of the reason 
that there has been some malcontent among the scientific community regarding the 
amyloid hypothesis revolves around the thought that all amyloid oligomers and plaques are 
toxic. While Aβ oligomers are clearly implicated in synaptic interruption, it is difficult to 
definitively say that Aβ is toxic to neurons since no convincing data has yet to be 
presented. Also, reports of successfully clearing of Aβ plaques from mice brains using 
immunization techniques does not clearly indicate the effects of Aβ on behavioral changes 
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(Schenk, Barbour et al. 1999). As far as clinical success with immunization techniques, it 
was concluded that although successful clearance of Aβ can be achieved, the end result of 
a rescue in cognitive function was not guaranteed since late stages of the disease are 
irreversible. However, administration of a vaccine or antibodies early in the disease 
progression could offer hope in delaying or halting the neurodegeneration (Boche, Zotova 
et al. 2008; Hardy 2009). Finally, there is a possibility that a double hit hypothesis is 
implicated more in onset of late-onset Alzheimer’s disease (LOAD). It provides a cause for 
how neurodegeneration induced by tau hyperphosphorylation appears in LOAD. But, it 
still leaves fundamental questions about the relationship between APP/Aβ and tau protein 
(Hardy 2009).  
 
Tau hyperphosphorylation 
Tau is a microtubule-associated protein abundant in neurons of the CNS and helps 
maintain normal neuronal functions, such as axonal transport and neuron stabilization. The 
components of microtubules are globular proteins called tubulins that weigh roughly 
55kDa. The tubulins come in many forms but the most common forms are the α-tubulins 
and β-tubulins. The interaction of tau with these tubulins helps stabilize the microtubule 
structure and promote its assembly within the cell. This is beneficial because it permits 
neurite expansion. The phosphorylation of tau results in the destabilization of the 
microtubule assembly. This results in a breakdown of microtubules that are necessary 
stages in many cell cycle functions, including cell division and mitosis. In Alzheimer’s 
disease, one of the major hallmark pathologies are aberrant structures of intracellular 
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neural tangles of hyperphosphorylated tau called neurofibrillary tangles (NFTs). NFTs are 
composed of tau proteins which aggregate to form structures called paired helical filaments 
(PHFs) (Maccioni, Munoz et al. 2001). These are the components to NFTs. 
Phosphorylation of tau occurs at more than thirty different serine/threonine residues in the 
AD brain by several kinases. Proline-directed kinases include GSK3β, CDK5, p38/MAPK, 
and JNK. Non-proline directed kinases include PKA, PKC, CaMKII, and MARK (Avila 
2006). Major focus has been towards GSK3β since this kinase has been extensively studied 
and characterized under pathological conditions. In familial Alzheimer’s disease (FAD), 
there are several mutations in genes that code for proteins clearly implicated in the 
facilitation of AD pathologies.  These include APP and the presenilin proteins, PS-1 and 
PS-2. Missense, deletion, and silent mutations in these genes have each been shown to 
result in the corresponding protein’s inability to bind protein phosphatase 2A, an enzyme 
responsible for the dephosphorylation of tau (Goedert, Satumtira et al. 2000). 
Consequently, the reduced ability to dephosphorylate results in a constitutively 
phosphorylated state of the tau protein, which leads to accumulation of NFTs. 
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Figure 4 Tau hyperphosphorylation begins when the microtubule associated protein tau is phosphorylated by 
several kinases which results in microtubule disassembly and concomitant aggregation of 
hyperphosphorylated tau. These form the intracellular NFTs which are neurotoxic. 
 
Amyloid deposition or Tau hyperphosphorylation? 
It is still unclear which major hallmark pathology is implicated to exert the more 
significant cognitive and memory deficits on the diseased brain in Alzheimer’s disease. 
The leading hypotheses have been narrowed down to amyloid plaque deposition and 
neurofibrillary tangles (NFTs). In the disease itself, the formation of NFTs strongly 
correlates with cognitive dysfunction, whereas amyloid plaque deposition does not produce 
cognitive dysfunction alone. Briefly, it has been studied and reported in a transgenic mouse 
model that tau phosphorylation plays an important and beneficial role in learning and 
memory and that only when tau becomes hyperphosphorylated does the cognitive decline 
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associated with AD and dementia begin (Boekhoorn, Terwel et al. 2006). A study 
published in the Journal of Neurochemistry in 2008 studied the temporal correlation 
between memory deficits and the activation of glycogen synthase kinase-3β (GSK-3β), 
which is a major kinase involved in tau phosphorylation and APP phosphorylation. The 
phosphorylation of these proteins facilitates the onset of the two major AD pathologies 
described above. The authors induced memory deficit and GSK-3β activation using 
WT/GFX, which has already been shown to induce spatial memory loss, and observed a 
time dependent correlation with GSK-3β activation and memory deficit (Wang, Zhang et 
al. 2008). Also, there was an increase in tau hyperphosphorylation that correlated with the 
memory deficit, but amyloid plaque deposition was not changed. Further, the amyloid 
plaque deposition increased after the memory deficits were regained by the injected mice. 
In this situation, these data suggest that tau hyperphosphorylation may be more important 
in AD-like memory deficits.  
As stated above, the phosphorylation and dephosphorylation of tau is a normal 
process in cell function and is important in microtubule assembly/disassembly and axonal 
transport.  If this process is natural to the living cell, then something must alter kinase and 
phosphatase functions involved with tau regulation. In another study, the authors sought to 
determine how tau might become hyperphosphorylated. They showed that aberrant 
glycosylation of tau proteins results in their becoming better substrates for major kinases 
involved in AD, such as CDK-5 and GSK-3β. The more efficient enzyme-substrate 
kinetics involved in tau hyperphosphorylation seems to be a possible answer because the 
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increase in tau phosphorylation does not correlate with an increase in CDK-5 and GSK-3 
expression in AD brains.  
Amyloid plaque formation is a somewhat ambiguous pathological hallmark but it is 
believed to be heavily involved in AD progression. There have been many studies showing 
that amyloid plaque formation occurs ahead of dementia and cognitive decline but this may 
be due to the eventual collapse of neurotrophic factors in the brain, including amyloid 
degrading enzymes and glial activation to remove the accumulated proteins. Also, the 
formation of amyloid does not always result in AD and may not even exert any form of 
mild cognitive impairment throughout the lifetime of affected individuals. But, the fact still 
remains that the presence of extracellular plaques disrupt neuronal synaptic connections 
and can induce a chronic inflammatory response, a situation in which neurotoxic 
chemokines and cytokines destroy neurons and their connections in the affected areas.  
Presenilin 1 is a subunit of the gamma secretase complex which facilitates amyloid 
processing into insoluble fragments that aggregate into the amyloid plaques. Genetic 
inactivation of the PS1 subunit in transgenic mice resulted in a substantial decrease in Aβ 
peptides and plaque formation (Saura, Chen et al. 2005). This in turn, resulted in a brief 
rescue in spatial memory and learning. However, the rescue in cognitive effects only 
occurred temporarily in short term PS1 inactivation as opposed to long term inactivation 
(Saura, Chen et al. 2005). Interestingly, there is increasing evidence that other biological 
systems are heavily involved in AD progression other than the usual players (i.e. PS1, 
APP, secretases, etc.) The tumor necrosis factor death receptor 1 (TNFR1) has been 
implicated in the regulation of BACE1 and thus regulates amyloid plaque deposition. He et 
  18
al.used mice lacking the TNFR1 receptor and showed that the amount of plaque generated 
was significantly reduced. In correlation with the decrease in Aβ, the learning and memory 
deficits usually attributed to mice in an AD model were prevented and rescued (He, Zhong 
et al. 2007). This evidence further supports the suggestion that amyloid protein generation 
is the main cause of memory and learning deficits associated with AD. So, if the amyloid 
protein seems to be relevant to the issue of memory and cognitive deficits, although this is 
not proven yet, it is vitally important to know how and why this is occurring as opposed to 
just what is causing it. It has been proposed that the reason amyloid plaque deposition does 
not correlate well with cognitive decline is because the deposited plaque is less of a threat 
to synaptic connections than soluble Aβ-derived oligomers and also, the memory 
impairments can occur before any amyloid plaque deposition is observed. Briefly, the best 
correlation for AD related dementia is to observe the synaptic density and to compare it 
with non diseased brains and it is this loss in synaptic density explains the memory loss 
seen in AD patients. Lacor et al provided evidence to support the idea that the soluble 
oligomers of APP can initiate neurotoxic mechanisms in cultured neurons, and thereby 
result in abnormal and dysfunctional dendritic spines in the synapse. The authors used 
highly differentiated hippocampal pyramidal neurons and exposed the soluble Aβ 
oligomers to them. The results were that less expression of memory-related receptors, such 
as NMDA, occurred after exposure and that the dendritic spine morphology began to 
resemble spines seen in other cognitive related diseases (Lacor, Buniel et al. 2007). In 
addition, a study of all-trans retinoic acid (ATRA) as a potential therapeutic for treating 
AD has shown that ATRA can attenuate amyloid plaque deposition by inhibiting cdk5 and 
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BACE1, both heavily involved in APP processing (Ding, Qiao et al. 2008). The inhibition 
of cdk5 and GSK-3β also results in the decerease in tau hyperphosphorylation at multiple 
epitopes. In the Morris water maze test of the treated mice, the spatial memory deficits 
were comparable to those of wildtype, while the untreated APP/PS1 mice displayed a 
profound loss of memory and no ability of spatial memory retention. These results suggest 
the idea that although tau hyperphosphorylation and amyloid plaque deposition have 
different etiologies, they are both significantly connected in AD. Treatment in the future is 
almost certain to combine some form of control over kinases involved, thus allowing a 
measure of control over both tau aggregation and APP processing. 
 
Genetics of Alzheimer’s disease 
There are two forms of AD; early onset, also known as familial AD (FAD), and late 
onset AD (LOAD). FAD occurs in less than five percent of the cases of AD, whereas late-
onset comprises the majority of AD cases. Both forms share very similar characteristics 
such as plaque formation, NFT formation, and similar distribution throughout the brain 
even though the genetics involved are as different as night and day. Since the 
groundbreaking achievement of mapping the human genome, it has become ever clearer 
that genetics play an important role in the onset of Alzheimer’s disease, especially familial 
AD. The human genome consists of roughly 30,000 genes. Within these genes, there are 
sequences of nucleic acids that contain the instructions to create proteins. Any alteration or 
mutation in this sequence can cause abnormal proteins to form and over time the build up 
of these abnormal proteins can cause disease. The genes involved with AD pathogenesis 
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are prevalent in early onset AD (familial AD) and manifest as an autosomal dominant form 
of inheritance. In familial AD cases, identification of the genes involved was narrowed to 
three: amyloid precursor protein (Goate, Chartier-Harlin et al. 1991), presenilin 1 
(Sherrington, Rogaev et al. 1995), and presenilin 2 (Levy-Lahad, Wasco et al. 1995). 
Mutations in these genes have been confirmed to intiate APP processing at an earlier age 
and have come to be known as Swedish mutations, referring to the people whom these 
genes were identified from. Although the discovery of these three genes were 
indispensable in furthering the etiology of AD, more and more evidence has pointed to a 
myriad of effects that contribute to late-onset AD which comprises almost 95% of all AD 
cases. In late-onset AD, the overexpression of APOE ε4 has been shown to be linked to a 
four-fold increase in developing AD (Strittmatter, Weisgraber et al. 1993). This gene is 
heavily involved with cholesterol levels and consequently, incidences of heart disease are 
also increased with the increase in risk of AD.  
Figure 5 describes the APP gene on chromosome 21. Mutations in the APP gene 
can result in cleavage and accumulation of the abnormal Aβ peptide which will lead to 
aggregation and formation of toxic neuritic plaques. It is also interesting to point out that 
aberrant expression of chromosome 21 (i.e. Trisomy 21, Down syndrome) in patients 
reveal a development of pathological hallmarks associated with AD. These include 
amyloid plaques, NFTs, and neuronal loss. The deposition of amyloid plaques occurs at an 
early age in Down syndrome patients and in late-onset AD patients, which further supports 
the notion that Aβ deposition precedes and may enhance other pathological changes. 
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Figure 5 Schematic drawing of APP and Aβ. The vertical dashed lines represent the single membrane 
spanning domain and the Aβ domain is represented by the solid black box. The lower drawing shows the 
amino acids of Aβ domain with the cleavage sites. 
 
(figure from http://www.scielo.cl/fbpe/img/rmc/v129n5/img14-01.gif) 
 
Inflammatory Hypothesis 
In most cases, the early symptoms of AD manifest through subtle losses in short 
term memory and gradually progress to total inability to recall any memory and dementia. 
What is interesting is that the formation of NFTs and amyloid plaque deposition do not 
account for every symptom associated with AD, especially in the early stages where 
neurodegeneration is not evident (Heneka and O'Banion 2007). One important facet of AD 
is the undisputed changes in inflammatory mechanism in the CNS that have been shown to 
facilitate the progression of AD symptoms. While it is true that all aging brains show signs 
of neuroinflammation, the diseased brain exhibits a much more profound case of activated 
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glial cells and inflammation (Heneka and O'Banion 2007). Amyloid plaques are diffusely 
covered with activated microglia and astrocytes. These glial cells, when stimulated, release 
several pro-inflammatory cytokines, chemokines, and complement that include TNF-α, IL-
1β, and various free radicals (Griffin, Sheng et al. 1998). While the initial inflammatory 
response to foreign antigens and wound healing changes are an important component of 
CNS health, the chronic overstimulation and activation of the glial cells contributes to 
neuronal dysfunction. Once these stimulators of glial cells begin, it creates a perpetual 
cycle of neuronal death that is difficult to impede (Abbas, Bednar et al. 2002)( Figure 6). 
In brief, it has been reported that fibrillar Aβ interacts with the lipopolysaccaride receptor, 
CD14, which causes the cell to secrete proinflammatory cytokines that in turn activate 
resident microglial cells in the brain (Fassbender, Walter et al. 2004) (Yan, Zhang et al. 
2003). Even more compelling is the report that microglia can kill neurons damaged by Aβ 
in a CD14 dependent process (Bate, Veerhuis et al. 2004). There is still much more work 
to be done in elucidating the exact mechanisms involved with immune system activation 
and response in relation to amyloid plaques because the role of fibrillar versus non-fibrillar 
Aβ and other forms have not been completely characterized. But, the significance of a 
specific receptor involved with Aβ signaling represents strong evidence that the innate 
immune response is an important player in the progression of AD.  
 Microglia are the resident macrophages within the CNS and play an important role 
in quick responses to foreign antigens, tumor invasion, and other forms of tissue injury. 
Representing roughly 10% of all cells in the CNS, they become activated and migrate in 
and around damaged cells to remove cellular debris and other protein fragments, such as 
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Aβ, through phagocytosis (Fetler and Amigorena 2005) (McGeer, Itagaki et al. 1988). In 
the case of AD, it has been shown that products of APP processing can activate glial cells 
and if this processing is inhibited, there is a corresponding decrease in glial activation 
(Schubert, Morino et al. 2000). As previously stated, the initial activation of microglia 
represents the body’s reaction to a neurotoxic stress, and the microglia’s ability to clear Aβ 
through phagocytosis is beneficial in that plaque deposition may be reduced (Yan, Zhang 
et al. 2003), although Landreth et al has shown that the same receptors responsible for 
phagocytosis cause super-oxide damage (Koenigsknecht and Landreth 2004) which 
contributes to neurotoxicity. Further, if chronically over activated, the constant release of 
cytokines initiates a perpetual cycle of neuronal death that will eventually overwhelm and 
destroy neuronal cells. This is the aspect of inflammation that is the target of therapeutics. 
If the chronic inflammatory state can be inhibited, then perhaps the beneficial aspects of 
microglial clearance and degradation can be enhanced and tip the balance of amyloid 
accumulation into a less damaging case.  
 Similar to microglia, the astrocytes have been shown to be able to clear amyloid 
plaques as well as provide neurotrophic support to neurons (Koistinaho, Lin et al. 2004) 
but this area is still debatable. They become over activated as well in a chronic 
inflammatory state. As is the case in microglia, it is not definitive that amyloid plaque 
deposition alone is enough to initiate this inflammatory response because it has been 
shown that activated astrocytes can occur in AD brains in the absence of amyloid 
deposition (Nunomura, Perry et al. 2001) since they respond to any neuron damage 
(Damiani and O'Callaghan 2007). Much work is being done now to discern the true cause 
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of glial activation in AD brains and whether or not this initiates APP processing or vice 
versa.  
 The human immune system is a complex network of mediators. The system as a 
whole must be taken into account when trying to deduce a mechanism of neuronal toxicity. 
Chemokines, cytokines, and other mediators such as complement can exert beneficial as 
well as detrimental effects on the CNS. For example, cytokines such as TNF-α and IL-1β 
have been shown to be able to suppress long term potentiation (LTP), a key process in 
memory formation, without damaging the neurons structurally (Tancredi, D'Antuono et al. 
2000). Neurons communicate via chemical neurotransmitters in the synapse, and this is 
believed to be the underlying basis for memory formation. Although the mechanisms are 
still being worked out, LTP functions by strengthening synaptic connections which can 
strengthen and retain learning and memory skills. This clearly shows how mediators of 
inflammation may exert the detrimental effect well before any sign of neuronal loss is 
observed (Heneka and O'Banion 2007). It is a balance of these molecules that is desired to 
create a “homeostatic” state where the body eliminates toxic antigens and promotes 
neuronal integrity. Inflammation is a key process in AD pathogenesis; there is more 
inflammation in the AD brain than in a patient after knee replacement surgery. Interference 
in the process of glial activation is a novel target of drug therapeutics. Although it does not 
attack the amyloid deposition directly, it could be beneficial in halting the 
neurodegenerative aspects of AD by promoting effective clearance and degradation of Aβ. 
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Figure 6 Diagram showing the perpetual “death” cycle initiated by activated microglia or neuronal damage. 
Intervention in this cycle is a therapeutic strategy that has been shown to alleviate neuronal damage and 
cognitive deficits associated with it.  
 
(from Block et al. Nature Reviews Neuroscience 8, 57  69 January 2007) 
 
Triptolide 
 
The drug being tested in this study is a major constituent of the Chinese herb, 
Tripterygium wilfordii Hook F, called Triptolide. It is a diterpenoid triepoxide and has 
structural similarities with steroids (see figure 7). The rationale for choosing such a drug 
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can be traced to previous studies involving Triptolide being used to treat rheumatoid 
arthritis, an inflammatory disorder, and some cancers through its antiangiogenic properties 
(He, Liu et al. 2009). With the recent discovery that Alzheimer’s disease brains display 
aberrant expression of cell cycle related proteins such as the cyclin-dependent kinases 
(CDKs), it was hypothesized that the use of anti-cancer drugs may have some effect in 
alleviating AD symptoms or even attenuates some pathology, including APP processing. 
For instance, treatment of APP/PS1 mice with indirubin, another Chinese herbal medicine 
for cancer, had alleviated AD pathologies including Aβ plaque load. It was later discovered 
through X-Ray crystallography that indirubin can bind to and inhibit CDK-2, eliminating 
its effects from over expression in diseased neurons. In the literature, Triptolide has been 
reported to suppress inflammation and cartilage destruction, inhibit prostaglandins via 
inhibition of cyclooxygenase (COX)-2, and reduce nuclear factor kappa B(NFκB) 
expression in vivo  (Lin, Liu et al. 2007). Triptolide has also been shown to inhibit the 
growth and metastasis of solid tumors through apoptosis induction and the reduction in 
expression of several cell cycle related molecules (Yang, Chen et al. 2003). In this same 
study, it proved to be more effective than conventional anti-tumor drugs such as 
adriamycin and cisplatin at inhibiting tumor cell proliferation. One of the most important 
effects of Triptolide related to Alzheimer’s disease was reported in 2008 in the Journal of 
Neuroimmunology. Triptolide inhibited the production of tumor necrosis factor-α (TNF-α) 
and interleukin-1β (IL-1β), both inflammatory cytokines known to be produced upon 
amyloid-β1-42 stimulation of neuronal cells (Jiao, Xue et al. 2008). This role of Triptolide is 
important because it is believed that the progression of Alzheimer’s disease can be halted if 
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chronic activation of the neuronal glial cells such as microglia and astrocytes can be 
inhibited or reduced. Previous work in this laboratory has tested many other Chinese 
herbal anti-cancer agents and some experimental agents developed for specific inhibition 
of certain neural processes. These include retinoic acid, a metabolite of vitamin A, 
indirubin, lupeol, both anti-cancer agents, and the CXCR-2 antagonist SB225002. CXCR-2 
is a chemokine responsible for many inflammatory mechanisms in the CNS. All of these 
drugs so far, have been proven to be beneficial in attenuating AD pathologies, such as APP 
processing and tau hyperphosphorylation, and able to rescue memory deficits in our AD 
mouse model as evidenced in the Morris Water maze acquisition test. The dose of 40µg/kg 
was decided as the appropriate dose to administer to the mice after carefully searching the 
literature and finding a study that administered varying concentrations of Triptolide to 
mice in order to discover its effects in arthritis (Lin, Liu et al. 2007). The effects of 
Triptolide were most prominent at a concentration of 32µg/kg. This corresponded to 0.625-
2.5% of LD50 for Triptolide (1.278mg/kg). There was no evidence of drug toxicity and no 
viscera damage. Even more, several studies characterizing the pharmacological toxicology 
of triptolide in mice indicated a safe dose as 0.03 mg/kg (Xu, Pan et al. 2008). Triptolide 
can cross the blood brain barrier fairly easily due to its lipophilic character and size (Wang, 
Liang et al. 2008). 
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Figure 7 Structure drawing of the triptolide molecule. Its four rings are homologous to corticosteroids, thus, 
it has similar effects in immunosuppression. 
 
(figure from  http://www.asiaandro.com/1008-682X/1/121f1.jpg, Wang et al, 1999) 
 
 
Figure 8 Mechanisms of the neuroprotective effects of triptolide. Overactive microglia in the CNS can lead 
to chronic release of cytokines and other inflammatory mediators which can kill dopaminergic neurons. 
Triptolide, aka T10, can inhibit the overactivation of microglia resulting in inhibition of the release of 
inflammatory cytokines, free radicals, NO, and Ca2+ overload.                                                                                                                   
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(figure from Wang, Liang et al 2008) 
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Materials and Methods 
 
 
Transgenic Mice and Triptolide treatment. There are many different mouse models 
available for the study of Alzheimer’s disease. For this study, we utilized APP/PS1 double-
transgenic mice from The Jackson Laboratory [strain name, B6C3-Tg (APPswe, 
PSEN1dE9)85Dbo/J; stock number 004462]. This particular strain of mice expresses a 
mutant chimeric mouse/human APP gene with Swedish mutations at K595N/M596L sites. 
There is also a presenilin 1 (PS1) human mutant with the exon 9-deleted variant. This 
variant is under the control of mouse prion promoter elements that directs the expression of 
these transgenes mainly to neurons of the CNS. The APP/PS1 mice were maintained as 
double hemizygotes by cross breeding with wild-type mice with a background strain of 
B6C3F1/J (stock number 100010), also from The Jackson Laboratory. To ensure proper 
genotype before each study, tail biopsies and PCR analysis of genomic DNA were 
performed. All animals were housed in the animal care facility at Virginia Commonwealth 
University medical campus and are in accordance with standard animal care protocols. 
Five month old wild-type mice and APP/PS1 mice were randomly assigned into four 
groups: untreated wild-type mice, treated wild-type mice, untreated APP/PS1 mice, and 
treated APP/PS1 mice. The treated groups received 40µg/kg of the drug Triptolide (Sigma, 
T3652), which was dissolved in normal saline with 5% DMSO in saline (vehicle). They 
were injected intraperitoneally three times weekly at 40µg/kg. The control groups received 
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an equal volume of 5% DMSO. Treatment of drug and vehicle control lasted 
approximately 8 weeks. The dose and regimen of treatment were based on previous reports 
describing effective therapeutic doses using Triptolide in mice and characterization of the 
pharmacokinetics involved (Blanchard, Moussaoui et al. 2003; Lin, Liu et al. 2007). The 
rationale for starting drug treatment at 5 months of age is based on previous reports that 
APP/PS1 mice of this particular strain begin to accumulate Aβ plaques as early as 5 
months of age. Although the expression of the mutant forms of these genes do not 
necessarily accurately describe the cases in sporadic late-onset AD, the lesions seen in all 
cases point to a final common pathway of pathologies that all sufferers of AD develop, 
human or mouse.  
 
Morris water maze test. After the treatment with Triptolide for 8 weeks, the memory and 
spatial learning was evaluated using the Morris water maze test (Morris 1984). The maze 
itself consists of a 120 cm diameter X 50 cm height circular and galvanized water tank. 
The area of the tank was divided into four equal quadrants and made opaque by the 
addition of milk powder. The water temperature was adjusted to 24 ± 1°C. An escape 
platform of 10 cm diameter was placed in one of the quadrants and submerged 2 cm below 
the water surface and at least 30 cm away from the side wall. Throughout the experiment, 
the platform was kept in the same quadrant. The mice were each gently placed in the maze 
always facing the tank wall, and were required to find the platform using only distal spatial 
cues in the testing room. For each trial, a different starting position was used. The mice had 
120s to find the platform and once they found it they were allowed to remain on the 
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platform for 10s. Then, the mice were taken out, dried, and placed in a separate cage for 
~60 minutes before the next trial. If a mouse failed to find the platform within the allotted 
120s, the experimenter assisted the mouse and subsequently allowed to stay on the 
platform for 10s. Between the trials, the water was stirred to erase olfactory traces of the 
previous mice.  Each animal was trained for four trials per day for five consecutive days to 
locate and escape onto the platform. Their spatial learning scores was measured as escape 
latency in seconds and recorded after each trial.  In order to assess the memory 
consolidation, a probe trial was conducted two days after the five day acquisition tests. 
During this trial, the platform was removed and the mice were allowed to swim freely in 
the tank. Time spent in the quadrant that had the platform during the acquisition tests was 
taken to indicate the degree of memory consolidation. All time measurements were done 
using a stopwatch by an experimenter blinded to which experimental group to which each 
animal belonged.  
 
Immunohistochemistry. After testing the spatial and learning memory of the mice, the mice 
were anesthetized with an intraperitoneal injection of ketamine (0.05 mg/kg) and perfused 
with PBS and subsequently 4% paraformaldehyde in PBS. The brains were removed and 
placed in 70, 96, and 99% ethanol solutions, respectively, for 2 hour intervals in order to 
dehydrate the brains completely. The brains were then left in xylene overnight and 
subsequently embedded in paraffin. The paraffin blocks were then sectioned horizontally 
by a microtome at 10µm. The sections were placed in a warm water bath and mounted onto 
SuperFrost Plus (Menzel-Glazer) glass slides. Sections were placed in 40° C for one hour 
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before being rehydrated and stained. Procedures for immunohistochemical staining were 
performed using coronal brain sections. The sections were deparafinned, rehydrated in 
various intervals of xylene and ethanol, and endogenous peroxide quenched with hydrogen 
peroxide [1% (v/v) in methanol]. They were then placed in 10mM sodium citrate buffer 
(pH 6) and microwaved for 15 minutes. After cooling to room temperature, they were 
incubated in blocking buffer [10% (v/v) goat normal serum (Millipore Bioscience 
Research Reagents) in PBSA containing 0.1% (v/v) Triton X-100 (Sigma)] for 60 minutes.  
Adding the appropriately diluted antibodies overnight at 4° C followed the blocking.  
 
Histochemistry. The paraffin-embedded brain sections were first deparafinned and 
rehydrated in various xylene and ethanol solutions following this protocol: 15 minutes 
xylene I; 15 minutes xylene II; 5 minutes 100% ethanol; 5 minutes 100% ethanol; 5 
minutes 95% ethanol; 5 minutes 85% ethanol; 5 minutes 70% ethanol; 5 minutes 50% 
ethanol; 5 minutes 30% ethanol; store in deionized water until ready for development. 
Subsequently, the sections were stained for the presence of Aβ plaque deposits using the 
Campbell-Switzer silver staining method (NeuroScience Associates). A detailed protocol 
for using this stain was generously provided by Dr. Bob Switzer of NeuroScience 
Associates in Knoxville, TN. The procedure begins after the rehydration of the brain 
sections by placing the sections in 2% ammonium hydroxide solution and shaking for 5 
minutes then placing in deionized water for 1 minute twice. Then, the sections are covered 
and placed in the SPC solution, a pyridine silver solution for the induction of nucleation 
sites, for 40 minutes while gently stirring. After the 40 minutes, the sections are placed in 
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1% citric acid solution for 3 minutes while shaking. Subsequently, the slides are placed in 
4.99 pH acetate buffer while the developing solution is prepared. The developing solution 
consists of making three separate solutions and then mixes them together to form the ABC 
solution. Solution A consists of 5g of sodium bicarbonate dissolved in 100mL of deionized 
water. Solution B consists of 0.2g of ammonium nitrate, 0.2g of silver nitrate, and 1.0g of 
silicotungstic acid all dissolved in 100mL of deionized water. Solution C consists of taking 
20mL of solution B and adding 140µL of 37% formaldehyde. All three solutions are mixed 
and stirred well. This ABC solution is then added to the brain sections, making sure to 
completely cover the brain tissue, and then incubated at room temperature until the plaques 
are developed. Once the desired results are obtained, the brain slides are washed in 4.99pH 
acetate buffer for 3 minutes. They are subsequently washed in deionized water for 30 
seconds, then a 0.5% thiosulfate buffer for 45 seconds, and then deionized water again for 
2 minutes. The slides are then available for additional staining or to be mounted.  
 
Image Analysis: Images for the DAB staining and Campbell-Switzer staining were taken 
with a Nikon TE2000-E inverted microscope, whereas immunofluorescent images were 
aquired with a Nikon TE2000-U confocal microscope under 40x oil immersion objective 
with numerical aperture (NA) 1.4, zoom 1.6. Fluorochromes were excited using a 488nm 
argon laser for FITC and a 543 nm helium-neon laser for Cy3, and the detector slits were 
configured to minimize any crosstalk between the channels.  
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Stereology: The stereological setup consisted of an Olympus BH-2 microscope (Olympus 
Life and Material Science Europe) with a high numerical aperture (NA 1.40) and oil 
immersion 100x objectives. This allows focusing in a thin focal plane inside a thick 
section. A camera transmits the image to a monitor on which a counting frame is 
superimposed using the computer-assisted stereological CAST-GRID software 
(Visiopharm). A motorized automatic stage was used to control movement in the x-y plane 
via a connected joystick. Movement in the z axis was done manually with the focus button 
on the microscope, and the distance between the upper and lower surfaces of the section 
and the height of the dissectors were measured with a Heidenhain microcator (model VRZ 
401) with a precision of 0.5 µm. The number of Aβ plaques in the hippocampal and 
cortical regions were counted using the optical fractionator method of unbiased 
stereological cell counting techniques. Aβ plaques or cells were sampled in counting 
frames of 644-988 µm2 [a(frame)] moved in x and y steps of 100 x 100 µm [a(step)]. The 
area sampling fraction (asf) was calculated as a(frame)/a(step). The thickness sampling 
fraction (tsf) was calculated as the height of the optical dissector probe (h) (8 or 10 µm) 
divided by the average height of the sections (t) (tsf=h/t). Aβ plaques were counted using a 
20x immersion lens. Total Aβ plaque or cell number (,) was estimated using the following 
equation: ,=Q- x 1/tsf x 1/asf x 1/ssf, where Q- is the number of cells counted, and ssf is 
the section sampling fraction. In the case of clusters of Aβ plaques, each cluster was 
counted as one plaque or cell and identified by the most clearly defined nucleus. 
Coefficients of error and variation were calculated as described previously (Wirenfeldt, 
Dalmau et al. 2003). The same sections that were sampled for number estimates were used 
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to estimate volume of Aβ plaques in cortical or hippocampal regions. The system software 
superposed a point grid at random over low-power (2.5x) magnified images of each 
section. Total reference volume (Vref) was estimated using the Cavalieri-point counting 
method (Gundersen and Jensen 1987), based on the sum of points that hit on each 
reference space, a(p) is the area per point on the grid, t is the mean section thickness (in 
millimeters), and k is the sampling interval. The same a(p) was used for estimating volume 
for both the cortical and hippocampal regions. The densities of Aβ plaques (number per 
cubic millimeter) were calculated by dividing the number counted by the total volume 
sampled of each reference space. The volume of sampled reference space was the number 
of dissectors multiplied by the volume of one dissector.  
 
Western blot analysis. Brain tissues were homogenized in TBS (20mM Tris-HCl buffer, 
pH 7.4, 150mM NaCl) containing several protease inhibitors such as, 0.5mM 
phenylmethylsulfonyl fluoride, 20µg/mL aprotinin, 20µg/mL leupeptin, 20µg/mL 
pepstatin, and 1mM EDTA. Approximately, there was 0.150g of brain tissue per 2 mL of 
TBS buffer. The brain homogenates were briefly sonicated and subsequently centrifuged at 
15,000 x g for 30 minutes. In order to determine protein concentration, the BCA protein 
assay (Pierce) was performed. The assay results were then used to determine proper 
loading amount. For each gel, 10µg of brain SDS supernatants were loaded in each well 
and run on 12% SDS polyacrylamide gel. The proteins were transferred at 300mA for 2 
hours to a polyvinylidene difluoride membrane (BioRad). After transfer, the membranes 
with the newly aquired proteins were incubated for at least 4 hours or overnight in 4°C 
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with specific antibodies to the proteins of interest. After incubation, the membranes were 
washed twice in 0.1% tween 20/TBS for 5 minutes. Subsequently, the membranes were 
then incubated at room temperature with the corresponding HRP-labeled secondary 
antibody for 1 hour (concentration always 1:2000). The ECL system was used for 
detection of labeling (GE Healthcare). This entailed placing radiographic film over the 
exposed membrane in a dark room and then developing it in a Kodak film developer. To 
ensure equal loading, β-actin antibody was used in the same procedure outlined above at 
concentration of 1:5,000. The observed bands were then analyzed using densitometric 
software (Scion Image). The following antibodies were used for western blot analysis: 
rabbit polyclonal anti-phosphorylated (p)-CDK5 (Ser 159) (1:500; Santa Cruz 
Biotechnolgy), mouse monoclonal anti-CDK5 (1:500; Santa Cruz Biotechnology), rabbit 
polyclonal anti-p-tau (Ser 404) (1:300; Santa Cruz Biotechnology), rabbit polyclonal anti-
p-GSK3β (Ser 9) (1:500; Santa Cruz Biotechnology), rabbit polyclonal anti-p-GSK3α/β 
(Tyr 279/Tyr 216) (1:500; Santa Cruz Biotechnology), rabbit polyclonal anti-GSK3β 
(1:500; Santa Cruz Biotechnology), mouse monoclonal anti-p-APP (Thr 668) (1:500; Cell 
Signaling Technology), rabbit polyclonal anti-APP-C-Terminal Fragments (CTFs) 
(1:3000; Sigma), mouse monoclonal anti-β-actin (1:5,000; Sigma), mouse monoclonal 
anti-GFAP (1:500; DakoCytomation).  
Iba-1, BACE1, PS1 
 
Statistical analysis. Presented data are expressed as the mean ± SEM and the analyses were 
performed using a two-way ANOVA followed by Fisher’s least significant difference post 
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hoc analysis to identify effects deemed to be significant. Differences were deemed 
significant at p < 0.05.
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Results 
 
 
Triptolide treatment prevents Aβ plaque accumulation in APP/PS1 mice 
Triptolide has been shown in the literature as a potent therapy for many cancers and 
rheumatoid arthritis but the effects on amyloid accumulation in APP/PS1 mice has not 
been characterized. After administration of triptolide intraperitonneally for 8 weeks on 5 
month old APP/PS1 mice and wild type littermates, the results in figure 9 show that 
triptolide treatment substantially decreased the amount of Aβ plaque accumulation in 
APP/PS1 mice compared to vehicle treated APP/PS1 mice. The areas observed include the 
frontal cortex and the hippocampus, a region that is involved in memory and learning. 
Stereological analysis also portrays a significant decrease in the amount of Aβ plaque 
levels. Plaque number, average volume, and area occupied by the amyloid plaques were all 
reduced in both the frontal and hippocampal brain regions of the APP/PS1 mice. Also, the 
vehicle treated APP/PS1 mice had no significant effects when compared to untreated mice 
of the same genotype and age (data not shown). These results support the idea that 
triptolide may be a possible therapeutic agent for inhibiting amyloid plaque deposition. A 
caveat to these results is that out of three samples subjected to amyloid staining and 
stereological analysis, one set of samples did not show a decrease in Aβ levels, but rather 
an increase in plaque accumulation. The reason for the antithetical result has yet to be 
determined.   
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Triptolide does not inhibit APP processing 
The current knowledge of amyloid processing indicates that APP plays a central 
role in the pathogenesis of plaque accumulation. APP CTFs are an early biomarker for the 
diagnosis for AD (Sergeant, David et al. 2002) and are a key step in the processing of APP. 
Western blot analysis using an anti-CTF antibody was used to determine whether APP was 
affected by the treatment with triptolide. This particular antibody recognizes the full-length 
APP protein as well as the CTFs. As shown in figure 10, we observed that APP expression 
is not changed between vehicle and drug treated mice. Interestingly, the CTFs were 
enhanced in the triptolide treated mice when compared to wild type. Also, the vehicle 
treated APP/PS1 mice did not show a significant difference in APP or CTF expression 
when compared to untreated mice of the same age (data not shown). To further explore the 
affects of triptolide on APP processing, an anti-BACE1 antibody was used to see whether 
the beta secretase enzyme was differentially expressed. Based on the western blot data in 
figure 10, it appears that BACE1 levels were not altered between the drug and vehicle 
treated groups. In keeping with the exploration of APP processing, an anti-phospho-APP 
antibody was used to see if the phosphorylation of the APP protein was affected in the 
drug treated mice. The phosphorylation of APP at Thr668 is important in the processing of 
this protein to cleavage and Aβ oligomer formation (Lee, Kao et al. 2003) and 
neurodegeneration (Chang, Kim et al. 2006). Again, as shown in figure 10, no significant 
change was seen across the group. The role of hyperphosphorylated tau is important when 
considering the clinical manifestations of AD. In this study, it was particularly difficult to 
obtain data that was consistent in showing whether tau was hyperphosphorylated or not. 
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Consequently, no data is presented that shows tau hyperphosphorylation in the APP/PS1 
mice even though it has been well documented that these mice exhibit excessive 
phosphorylation at several tau epitopes (Kurt, Davies et al. 2003). Nevertheless, according 
to the amyloid hypothesis, the role of tau hyperphosphorylation in relation to memory loss 
appears to occur downstream of plaque formation and deposition which leads many to 
believe that its role in neurodegeneration is secondary to amyloid processing. This is, 
however, a very much debatable area in AD research and it should be emphasized that 
there is no definite consensus on how the mechanistic cascade of AD plays out.  Kinases 
known to be implicated in AD include CDK5 and GSK3β. These are involved in tau 
hyperphosphorylation (Singh, Grundke-Iqbal et al. 1994; Hartigan and Johnson 1999) and 
APP phosphorylation (Aplin, Gibb et al. 1996; Iijima, Ando et al. 2000). According to 
figure 10, observing the activity of CDK5 and GSK3β, we can conclude that the 
administration of triptolide has no effect on the enzyme activity or expression levels. The 
expression remained unchanged between drug treated APP/PS1 mice and vehicle treated 
APP/PS1 mice. Assessing the activity of GSK3β, the results were similar to that of CDK5. 
The levels of protein expressed in drug treated versus vehicle treated APP/PS1 mice were 
unchanged, indicating that triptolide has no effect on changing the activity of GSK3β. 
Together, the data concludes that the activities of the major kinases of tau and APP 
processing are unchanged by triptolide treatment.   
 
Triptolide treatment reduces the number of glia associated with Aβ plaques in 
APP/PS1 mice   
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It has been well documented that APP/PS1 mice as well as AD patients exhibit 
enhanced reactivity of glial cells such as microglia and astrocytes. These glial cells are in 
and around Aβ plaques and appear to be the results of an inflammatory reaction caused by 
these diffuse plaque depositions. This is very characteristic of inflammatory mechanisms 
that occur when injury presents itself in the brain (McGeer and McGeer 1999). Triptolide 
has been shown in vitro to inhibit inflammatory cytokines such as IL-1β and TNF-α in 
response to amyloid oligomer stimulation (Jiao, Xue et al. 2008). The activated microglia 
was visualized by immunohistochemical techniques using an Iba-1 antibody. Double 
staining of Iba-1 and amyloid plaques shows that activated microglia are localized in and 
around the deposited plaques. In figure 11, there is a significant increase in Iba-1 
immunoreactivity around the amyloid plaque in the vehicle treated APP/PS1 mouse brain 
as compared to the triptolide treated APP/PS1 mouse brain. However, it is difficult to 
determine if the amount of microglial cells in the drug treated APP/PS1 mouse brain is the 
result of a significant inhibition by triptolide or from the significant decrease in Aβ plaque 
deposits.  
The activated astrocytes were visualized using immunohistochemical techniques 
using a GFAP antibody. Similar to the microglia, the double staining of astrocytes and Aβ 
plaques showed that the astrocytes indeed were in and around the plaque deposits. The 
amounts of activated astrocytes around the plaques were significantly reduced in the 
triptolide treated APP/PS1 mouse brain when compared to the vehicle treated APP/PS1 
mouse brain. This is similar to the microglia results but similar conclusions cannot be 
drawn from the data since astrocyte migration activity differs from microglia (Pihlaja, 
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Koistinaho et al. 2008). Thus, it is still unclear whether the reduction in glial activation is a 
result of triptolide’s action as an immunosuppressant or from the substantial decrease in 
amyloid plaques. 
 
 
Triptolide treatment rescues learning and memory deficits in APP/PS1 mice 
The mouse model used in this study was an APP/PS1 double transgenic mouse line 
that is well characterized. This model has been consistently reported to develop Aβ plaques 
associated with cognitive deficits as the mice age (Trinchese, Liu et al. 2004). Based on the 
Morris water maze test, the results of our investigation in figure 12 show that after 
treatment with triptolide, the APP/PS1 mice exhibited a substantial improvement in 
memory as proven by the decrease in escape latency across trials. Improvement of memory 
retention in the drug treated APP/PS1 mice was also evidenced by the probe trial. In 
contrast, the data illustrate that the vehicle treated APP/PS1 mice portrayed an inability to 
acquire the learning and memory exhibited by wild type and triptolide treated mice. It 
should be noted that the deficits in the acquisition and probe trial were not attributable to 
different swim speeds since APP/PS1 mice and wild type mice exhibit similar swimming 
abilities. Based on these results, it can be concluded that triptolide is beneficial in retaining 
cognitive abilities in APP/PS1 mice. 
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Figure 9 Triptolide treated APP/PS1 mice show reduced levels of Aβ deposits when compared with 
vehicle treated APP/PS1 mice. A represents Campbell-Switzer staining in the frontal cortex of 
  45
APP/PS1 mice treated with vehicle (left) and triptolide (right). B represents Campbell-Switzer staining 
in the frontal cortex of APP/PS1 mice treated with vehicle (left) and triptolide (right). C represents 
stereological quantification of Aβ plaque number in the hippocampus. D represents stereological 
quantification of Aβ volume in the hippocampus, all described in the Materials and Methods. Values 
from multiple images of each section were averaged per animal per experiment. Data are mean ± SEM 
from three mice per genotype. *p<0.05 versus vehicle treated control APP/PS1 mice. 
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Figure 10 Triptolide treatment had no change on the expression of APP and did not reduce the amount of 
CTFs. Western blots for APP, APP-CTFs, phosphorylated-APP, BACE1, PS1, phosphorylated GSK3α,β 
(Tyr 216), phosphorylated CDK5 (Ser 159), CDK5, and β-actin. 
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Figure 11 Triptolide treatment appears to cause a reduction in microglial reactivity in the APP/PS1 mice 
brains. A represents Campbell-Switzer staining for Aβ and immunostaining of Iba-1 in the hippocampal CA3 
region. Wild-type (WT) and APP/PS1 mice with vehicle or triptolide are shown. There are less activated 
microglia in the triptolide treated APP/PS1 mouse brain than in the vehicle treated APP/PS1 mouse brain. B 
represents Western blot analysis of Iba-1 expression among the four genotypes. A slight reduction can be 
seen in the triptolide treated versus vehicle. 
  48
WT, Veh
APP/PS1, Veh
WT, Triptolide
APP/PS1, Triptolide
A
 
 
 
 
 
 
 
 
 
 
 
  49
                Hippocampus                    Cortex   
               VEH       VEH     TRI      TRI     VEH     VEH    TRI    TRI 
GFAP
B W
T
W
T W
T
W
T
A
P
P
P
S
1
A
P
P
P
S
1
A
P
P
P
S
1
A
P
P
P
S
1
 
Figure 12 Triptolide treatment appears to cause a reduction in astrocyte reactivity in the APP/PS1 mice 
brains. A represents Campbell-Switzer staining for Aβ and immunostaining of GFAP in the hippocampal 
region. Wild-type (WT) and APP/PS1 mice with vehicle or triptolide are shown. There is less activated 
astrocytes in the triptolide treated APP/PS1 mouse brain than in the vehicle treated APP/PS1 mouse brain. B 
represents Western blot analysis of GFAP expression among the four genotypes. There appears to be no 
significant reduction in the triptolide treated brain versus the vehicle treated brain. 
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Figure 13 Treatment of APP/PS1 mice with triptolide results in attenuation of AD-type spatial memory 
deterioration. A represents acquisition of spatial learning in the Morris water maze hidden platform task. 
APP/PS1 mice treated with triptolide displayed learning similar to wild-type mice; while vehicle treated 
APP/PS1 mice displayed learning deficits. Latency score represents the time taken to escape to the platform 
from the water. Lines represent mean ± SEM from six to eight mice (indicated) per group. B represents the 
memory test in the Morris water maze probe trial without the platform. The deficits in the vehicle treated 
APP/PS1 mice were improved in the triptolide treated APP/PS1 mice. Error bars represent mean ± SEM from 
six to eight mice (indicated) per group. *p< 0.05, **p< 0.01 versus vehicle treated control APP/PS1 mice. 
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Discussion 
 
 
As stated above, triptolide’s therapeutic potential has been exploited for the use in 
rheumatoid arthritis and certain cancers. Its structure has similar homology to 
corticosteroids and thus is a potent immunosuppressant. This aspect of immunosuppression 
is believed to play a beneficial role in the inflammatory mechanisms of AD and help bring 
the patient’s immune system to a state of effectively clearing amyloid plaques from the 
CNS. This is further supported by several epidemiological studies suggesting a potential 
benefit from using anti-inflammatory drugs on AD patients (Akiyama, Barger et al. 2000). 
Inflammatory processes in the CNS become detrimental to the AD patient. This is believed 
to be caused by activated glial cells that target senile amyloid plaques for degradation but 
in the process can damage neurons in and around the plaque deposits. Therefore, a possible 
solution for treatment in conjunction with inhibiting plaque formation would be to inhibit 
glial cell activation. Certain drugs have shown promise as treatments for AD and clinical 
trials are currently being done to study the effectiveness of such anti-inflammatory 
treatment. However, the mechanisms of action for this avenue of therapy still remains 
elusive since cytokines released from glial cells have neurotrophic as well as neurotoxic 
effects (Richartz, Stransky et al. 2005). This study has indicated that treatment of APP/PS1 
double transgenic mice with triptolide can attenuate amyloid plaque deposition which 
concordantly will halt deficits in learning and memory. It has been reported that the effects 
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of anti-inflammatory drugs may not act via inhibition of prostaglandins but actually 
reducing the plaque burden on the CNS (Cirrito and Holtzman 2003). The aspect of 
cognitive deficits is the chief clinical manifestation of AD and arguably the central target 
of any drug therapy. Again, triptolide’s effect on the immune system is a possible 
explanation for the halt of neurodegeneration and rescue of spatial learning and memory 
exhibited in treated mice. Of the two chief protein aggregates, only amyloid plaque 
deposition was observed to have been attenuated by treatment with triptolide. The 
Campbell-Switzer stain is a reliable silver stain for amyloid plaques in brain sections. 
Expression of the APP protein was not changed among the triptolide treated and vehicle 
treated APP/PS1 mice which indicates that triptolide had no effects on APP gene 
transcription. However, there was an elevated presence of CTFs, the cleavage products of 
alpha, beta, and gamma secretases. This clearly indicates that cleavage of the APP protein 
is not hindered and in fact may be enhanced at a specific point along the processing. The 
preclusion of plaques from the histological staining of the brain sections of APP/PS1 mice 
treated with triptolide can be explained by an enhanced clearance and degradation of 
plaque deposits. However, the activity of gamma secretase can also be part of the 
explanation since this enzyme is still poorly understood in its function. An enhanced level 
of inflammatory mediators in the APP/PS1 mice have been shown to increase BACE1 
activity in the hippocampus and result in an increase in CTFs (Blasko, Beer et al. 2004). 
Also, gamma secretase has been shown to increase in expression in response to activated 
glial cells from brain injury (Nadler, Alexandrovich et al. 2008). In keeping with the idea 
that inflammation is heavily involved in the pathogenesis of AD, it should be noted that 
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certain benefits can arise from inflammatory mechanisms. This depends on which 
mediators are involved, the time the disease develops, and whether the response is chronic 
or acute inflammation (Sastre, Walter et al. 2008). Microglia can clear amyloid plaques 
through phagocytosis and release elements of neuroprotection such as glia-dervied 
neurotrophic factor (GDNF) (Liu and Hong 2003). Interestingly, it has been reported that 
microglia already activated from newly formed amyloid plaques can restrict the growth of 
the plaques if further activation of microglia is inhibited (Meyer-Luehmann, Spires-Jones 
et al. 2008). Since triptolide has been shown to inhibit inflammatory cytokine release, it is 
certainly possible that the clearance of amyloid by glial cells and the formation of new 
plaques keep each other in “balance” and reach a steady state of formation and clearance. 
Further testing would be needed to support the hypothesis of a reduction in microglia 
activation with triptolide treatment.  With the gamma secretase complex, the situation 
becomes even more unclear. A recent study has shown that some anti-inflammatory drugs 
can directly modulate the activity of gamma secretase (Czirr and Weggen 2006). The 
gamma secretase is composed of four essential membrane proteins: aph-1, pen-2, nicastrin, 
and presnilin (PS) (Sastre, Walter et al. 2008). It has been reported that activated glial cells 
have an increase in expression of presenilin (Nadler, Alexandrovich et al. 2008) but it is 
still unknown whether this can affect the glial cell function. Further, in cases of familial 
AD (FAD), where the patient displays amyloid plaques earlier than usual, there is a 
positive correlation with an increase in inflammatory processes. Again, it is unclear 
whether the increase in presenilin promotes neuroinflammation through other pathways or 
whether it promotes neuroinflammation through a substantial increase in amyloid plaque 
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deposition (Sastre, Walter et al. 2008). Using figure 7 again, and based on the results of the 
experiment, there are a few mechanisms that triptolide could be exploiting in exerting its 
beneficial aspects in the APP/PS1 mice. Triptolide is very much possibly interacting at the 
specific receptors for microglia activation. It has been shown to inhibit specific cytokine 
production and NO production, thereby inhibiting microglial receptor activation. However, 
no evidence has shown that superoxide formation is inhibited and this is believed to be of 
paramount importance in glial cell activation. The reduction in cytokine production will 
also inhibit glutamate and Ca2+ excitotoxicity, as stated in the introduction, and can 
therefore reduce cell death. While these mechanisms are plausible for explaining an 
inhibition of neuronal cell death, thereby enhancing learning and memory in the APP/PS1 
mice, it does not provide an adequate explanation for a reduction in amyloid plaque 
deposition.   
This study also attempted to investigate the prevalence of tau hyperphosphorylation 
among the four genotype mice tested. Unfortunately, the western blot analysis of brain 
homogenates yielded conflicting and inconsistent data (data not shown). Therefore, it was 
determined that the study would forego any further attempt to assess the reason for this as 
it seemed beyond the scope of this project. The absence of any tau hyperphosphorylation 
data appears to be inconsequential when measuring the cognitive deficits in the Morris 
water maze although many believe that it is closely linked with neuronal damage. It should 
be further explored as to why this pathological hallmark of AD did not manifest itself in 
these groups of mice or some technological error occurred that is responsible for the 
conflicting data. When it comes to the major kinases involved with tau 
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hyperphosphorylation (Lovestone and Reynolds 1997), we see that there appears to be no 
change between the triptolide treated and vehicle treated APP/PS1 mice. The expression of 
total CDK5 remained constant throughout the four genotypes, indicating no change in 
expression of the inactivated form of CDK5, phosphorylated CDK5. GSK3 also showed no 
change.  
Since triptolide has been shown to inhibit inflammatory cytokines and chemokines, 
it was expected that glial activation might be reduced in the diseased CNS to a 
neurotrophic level. And indeed the APP/PS1 mice treated with triptolide did appear to 
exhibit a decrease in glial number in cortical and hippocampal regions. It is unclear 
whether the decrease in glial activation is the result of a decrease in Aβ plaque deposits or 
whether triptolide’s anti-inflammatory properties inhibited the activation directly. 
Microglia change has so many parameters including morphology, number, and cytokine 
production. But, the appearance of a decrease in glial number supports an anti-
inflammatory effect and thus can be beneficial and effective in neurodegenerative 
disorders, such as AD. 
This study demonstrates that administration of triptolide can reverse or inhibit 
spatial learning and memory deficits associated with APP/PS1 mice. The cognitive 
dysfunction associated with these mice is a result of an accelerated production of amyloid 
plaques and loss of functional synapses (Chen, McPhie et al. 2000). Although it is clear 
that triptolide attenuated the amyloid plaque accumulation in brains of APP/PS1 mice 
relative to vehicle treated APP/PS1 mice, it cannot be definitively ruled out that triptolide 
exerts its neuroprotective effects through other mechanisms. However, a possible solution 
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rests with the evidence that triptolide has neuroprotective effects on dopaminergic neurons 
which can increase and/or keep intact the ability to release cholinergic neurotransmitters 
that can protect against the cytotoxic effects of Aβ (Wang, Liang et al. 2008). 
This study has provided evidence that triptolide can inhibit amyloid plaque deposit 
and other neuropathologies associated with AD. Also, cognitive deficits associated with 
APP/PS1 double transgenic mice were ameliorated. The long historical use of this Chinese 
herbal derivative has now been characterized in an AD mouse model and hopefully will 
lead to clinical trials where the effects can be further explored in human AD patients.  
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Future Studies 
 
 
The present study has done a lot to answer the question of whether or not triptolide 
can be a beneficial therapeutic for treating Alzheimer’s disease. There is a substantial 
decrease in amyloid plaque deposits and glial activation. Memory and learning abilities 
appeared to be rescued in the drug treated APP/PS1 mice relative to vehicle treated 
APP/PS1 mice. Although these are exciting results, the exact mechanism of triptolide’s 
effects have not been elucidated. A more extensive study of gamma secretase could 
possibly reveal much in how the anti-inflammatory property of triptolide affects its 
activities. A more extensive study of the phagocytic ability of microglia in the dystrophic 
brain treated with triptolide may provide an answer to how the brain can inhibit the 
accumulation of Aβ. This would involve phagocytosis assays and electron microscopy 
studies of brain tissue. A thorough assessment of changes in synaptic integrity using 
drebrin and synaptophysin markers can provide direct evidence for an inhibition of 
neurodegeneration in triptolide treated mice. Further studies of iNOS changes and cytokine 
and super-oxide release in relation to AD and triptolide treatment can explain glial 
activation mechanisms and anti-inflammatory effects of triptolide. And finally, 
administration of triptolide in a much older APP/PS1 mouse model could fully answer the 
question of whether triptolide can attenuate and decrease Aβ accumulation. Complications 
would likely arise when trying to establish a rescue in memory deficits since neuronal 
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death cannot be reversed. Nevertheless, much work remains in fully characterizing 
triptolide’s therapeutic affects and the results presented in this study will perhaps further 
the study of anti-inflammatory drug therapy, an avenue that has proven to be 
neuroprotective and inhibit hallmark pathological symptoms. 
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